The report of non-tyrosine kinase inhibitor market in oncology in the period of 2015 to 2025 was released early in April of this year. Some of the data mentioned in the report is worth to be taken notice and from it, the drug research and discovery trend in this area can be predicted. Besides, some interesting facts presented in the report can be a reference for small companies to get developed in the area while tyrosine kinase inhibitor has been the main type of anti-cancer drug and the practitioners of it are commonly giant companies.
Molecular level of targeting at the cancer cells or related proteins is the most effective way to treat cancer at present. Kinase inhibitors are drugs that target protein kinase to achieve the aim of slowing the cancer cells’ growth and inhibiting their activities. Kinase inhibitor drugs mainly include tyrosine kinase inhibitors and non kinase inhibitors, but the former takes up a dominating place in the field.
As non tyrosine kinase inhibitor drugs are increasingly developed by scientists and show a great potential in providing better medication for cancer, the report was set out. According to the statistics from the report that there are in total seven non tyrosine kinase inhibitors approved by the related department, and the number is increasing.
In the report, the approved non tyrosine kinase inhibitor, the general information of the companies that made the success, ongoing researches and market indication were all presented to give an over-round prediction of the future market trends. It’s estimated that non tyrosine kinase inhibitor will embrace an increase both in R&D and sales in next few years, from which it can be seen that small companies will experience a chance to expand their business by joining in the field that have been led by big companies.
More information about the report can be accessed at the website of research and markets with title of Non-Tyrosine Kinase Inhibitors in Oncology, 2015 – 2025.
- Global Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 – mTOR inhibitors (53%) and RAF/MEK inhibitors (46%) are the main contributors to the market, published on Nov. 10, 2015 at Globe News Wire
- Non-Tyrosine Kinase Inhibitors in Oncology, 2015 – 2025, published in April, 2015 at Research and Markets
Related Products at BOC Sciences